uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2019-26-1-9-19uzspbgmu-567Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ЛЕЧЕНИИ ХРОНИЧЕСКОЙ ВОСПАЛИТЕЛЬНОЙ ДЕМИЕЛИНИЗИРУЮЩЕЙ ПОЛИНЕЙРОПАТИИ (обзор литературы)AN UPDATE DATA ON THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (review of literature)https://orcid.org/0000-0002-4440-8353ГапешинР. А.GapeshinRoman A.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8.

6-8 L’va Tolstogo street, St. Petersburg, 197022

gapeshin.ra@gmail.comБаранцевичЕ. Р.BarantsevichEvgeny R.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8.

6-8 L’va Tolstogo street, St. Petersburg, 197022

professorerb@mail.ruРуденкоД. И.RudenkoDmitry I.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8.

6-8 L’va Tolstogo street, St. Petersburg, 197022

dmrud_h2@mail.ruПосохинаО. В.PosokhinaOksana V.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8.

6-8 L’va Tolstogo street, St. Petersburg, 197022

o.v.posokhina@mail.ruСтучевскаяТ. Р.StuchevskayaTima R.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8.

6-8 L’va Tolstogo street, St. Petersburg, 197022

timamd@gmail.comФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияPavlov UniversityRussian Federation201905042019261919Copyright © Гапешин Р.А., Баранцевич Е.Р., Руденко Д.И., Посохина О.В., Стучевская Т.Р., 20192019Гапешин Р.А., Баранцевич Е.Р., Руденко Д.И., Посохина О.В., Стучевская Т.Р.Gapeshin R.A., Barantsevich E.R., Rudenko D.I., Posokhina O.V., Stuchevskaya T.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/567

Хроническая воспалительная демиелинизирующая полинейропатия (ХВДП) – это клинически гетерогенная иммуноопосредованная периферическая нейропатия, имеющая прогрессирующее или рецидивирующее-ремиттирующее течение. Общая встречаемость ХВДП составляет около 1–8,9/100 000. В настоящее время для лечения ХВДП используют три основных вида терапии – глюкокортикостероиды, внутривенные иммуноглобулины и плазмаферез. При неэффективности или недостаточном эффекте данных видов лечения также применяют цитостатики, моноклональные антитела и другие препараты. В данной статье приводятся современные данные о применении основных методов лечения в терапии ХВДП, о механизмах их действия, показаниях к использованию того или иного препарата, а также преимуществах и недостатках каждого из них.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous immune-mediated peripheral neuropathy with progressive or relapse-remitting course. Incidence of CIDP ranged between 1 and 8.9/100 000. Recently, most frequent therapies for CIDP treatment was glucocorticosteroids, intravenous immunoglobulin and plasma exchange. In cases of ineffectiveness or lack of effectiveness, cytostatics, monoclonal antibodies and others could be used for CIDP treatment. In the article, authors presented an update data on the use of main methods for CIDP therapy, their mechanisms of action, indication for their use and advantages and disadvantages of each of them.

хроническая воспалительная демиелинизирующая полинейропатияглюкокортикостероидывнутривенный иммуноглобулинплазмаферезлечениеэлектронейромиографияаутоиммунное заболеваниеchronic inflammatory demyelinating polyneuropathyglucocorticosteroidsintravenous immunoglobulinplasma exchangetreatmentelectroneuromyographyautoimmune diseaseReferencesBril V., Blanchette C. M., Noone J. M. et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy // J. Diabetes Complications. – 2016. – Vol. 30, № 7. – Р. 1401–1407. http://dx.doi.org/10.1016/j.jdiacomp.2016.05.007.Bril V., Blanchette C. M., Noone J. M. et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016;30(7):1401– 1407. http://dx.doi.org/10.1016/j.jdiacomp.2016.05.007.Laughlin R. S., Dyck P. J., Melton L. J. et al. Incidence and prevalence of CIDP and the association of diabetes mellitus // Neurology. – 2009. – Vol. 73, № 1. – Р. 39–45.Laughlin R. S., Dyck P. J., Melton L. J. et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39–45.Lefter S., Hardiman O., Ryan A. M. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland // Neurology. – 2017. – Vol. 88, № 3. – Р. 304–313.Lefter S., Hardiman O., Ryan A.M. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88(3):304–313.Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants : where we are and where we should go Clinical Presentation: One or More // J. Peripher. Nerv. Syst. – 2014. – № 13. – Р. 2–13.Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go Clinical Presentation: One or More. J Peripher Nerv Syst. 2014;13:2–13.Турсынов Н. И., Григолашвили М. А., Илюшина М. Ю. и др. Современные аспекты диагностики и лечения хронических демиелинизирующих полинейропатий // Нейрохир. и неврол. Казахстана. – 2016. – Т. 3. № 44. – С. 38–45.Tursynov N. I., Grigolashvili M. A., Iluyshina N. Yu. et al. Modern aspects of diagnosis and treatment of chronic demyelinated polyneuropathies. Neurosurgery and Neurology of Kazahstan. 2016;3(44):38–45. (In Russ.).Roux T., Debs R., Maisonobe T. et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases // J. Peripher. Nerv. Syst. 2018. http://dx.doi.org/10.1111/nep.12287 .Roux T., Debs R., Maisonobe T. et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. J Peripher Nerv Syst. 2018. http://dx.doi.org/10.1111/nep.12287.Press R., Hiew F. L., Rajabally Y. A. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: Evidence base and clinical practice // Acta Neurol Scand. – 2016. – Vol. 133, № 4. – Р. 228–238.Press R., Hiew F. L., Rajabally Y. A. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: Evidence base and clinical practice. Acta Neurol Scand. 2016;133(4):228–238.Czock D., Keller F., Rasche F. M. et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids // Clin. Pharmacokinet. – 2005. – Vol. 44, № 1. – Р. 61–98.Czock D., Keller F., Rasche F. M. et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.Strehl C., Buttgereit F. Optimized glucocorticoid therapy: Teaching old drugs new tricks // Mol. Cell. Endocrinol. – 2013. – Vol. 380, № 1–2. – Р. 232–240. http://dx.doi.org/10.1016/j.mce.2013.01.026.Strehl C., Buttgereit F. Optimized glucocorticoid therapy: Teaching old drugs new tricks. Mol Cell Endocrinol. 2013;380 (1– 2): 32–40. http://dx.doi.org/10.1016/j.mce.2013.01.026.Kleyman I., Brannagan T. H. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy // Curr. Neurol. Neurosci. Rep. – 2015. – Vol. 15, № 7.Kleyman I., Brannagan T.H. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy. Curr Neurol Neurosci Rep. 2015;15(7).Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan / E. Nobile-Orazio, F. Gallia, F. Terenghi, M. Bianco // Expert Rev. Neurother. – 2017. – Vol. 17, № 8. – Р. 755–765. https://doi.org/10.1080/14737175.2017.1340832.Nobile-Orazio E., Gallia F., Terenghi F., Bianco M. Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan. Expert Rev Neurother. 2017;17(8):755–765. https://doi.org/10.1080/14737175.2017.1340832.van Schaik I. N., Eftimov F., van Doorn P. A. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial // Lancet Neurol. – 2010. – Vol. 9, № 3. – Р. 245–253.Schaik I.N., Eftimov F., van Doorn P. A. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245–253.Muley S. A., Kelkar P., Parry G. J. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With Pulsed Oral Steroids // Arch. Neurol. – 2008. – Vol. 65, № 11. – Р. 1460–1464. https://doi.org/10.1001/archneur.65.11.1460.Muley S. A., Kelkar P., Parry G. J. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With Pulsed Oral Steroids. Arch. Neurol. 2008;65(11):1460–1464. Doi: 10.1001/archneur.65.11.1460Börü Ü. T., Erdoǧan H., Alp R. et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-Year follow up // Clin. Neurol. Neurosurg. – 2014. – № 118. – Р. 89–93.Börü Ü.T., Erdoǧan H., Alp R. et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-Year follow up. Clin Neurol Neurosurg. 2014; 118:89–93.van Lieverloo G. G. A., Peric S., Doneddu P. E. et al. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone // J. Neu- rol. – 2018. – Vol. 265, № 9. – Р. 2052–2059. http://dx.doi.org/10.1007/s00415-018-8948-y.Lieverloo G. G. A., Peric S., Doneddu P. E. et al. Cortico steroids in chronic inflammatory demyelinating polyneuropathy: A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol. 2018;265(9):2052–2059. http://dx.doi.org/10.1007/s00415-018-8948-y.Dalakas M. C. Potential biomarkers for monitoring therapeutic response in patients with CIDP // J. Peripher. Nerv. Syst. – 2011. – № 16, Supple 1. – P. 63–67.Dalakas M. C. Potential biomarkers for monitoring therapeutic response in patients with CIDP. J Peripher Nerv Syst. 2011;16(Suppl. 1):63–67.Lünemann J. D., Nimmerjahn F., Dalakas M. C. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy // Nat. Rev. Neurol. – 2015. – Vol. 11, № 2. – Р. 80–89. Available at: http://www.nature.com/doifinder/10.1038/nrneurol.2014.253 (дата обращения 12.05.2019).Lünemann J. D., Nimmerjahn F., Dalakas M. C. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–89. Available at: http://www.nature.com/doifinder/10.1038/nrneurol.2014.253 (accessed 12.05.2019).Van den Bergh P. Y. K., Hadden R. D. M., Bouche P. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the // Eur. Federation of Neurological Societies and the Peripher. Eur. J. Neurol. – 2010. – Vol. 17, № 3. – Р. 356–363. http://doi.wiley.com/10.1111/j.1468-1331.2009.02930.x.Van den Bergh P. Y. K., Hadden R. D. M., Bouche P. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol [Internet]. 2010;17(3):356–363. http://doi.wiley.com/10.1111/j.1468-1331.2009.02930.x.Lunn M. P., Ellis L., Hadden R. D. et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies // J. Peripher. Nerv. Syst. – 2016. – Vol. 21, № 1. – Р. 33–37.Lunn M. P., Ellis L., Hadden R. D. et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst. 2016;21(1):33–37.Iijima M., Yamamoto M., Hirayama M. et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP // Neurology. – 2005. – Vol. 64, № 8. – Р. 1471–1475.Iijima M., Yamamoto M., Hirayama M. et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology. 2005;64(8):1471–1475.Finsterer J., Aliyev R. Chronic inflammatory demyelinating polyneuropathy variant with creatine-kinase elevation and vanishing effect of immunoglobulins // Am. J. Case Rep. – 2017. – № 18. – Р. 834–838.Finsterer J., Aliyev R. Chronic inflammatory demyelinating polyneuropathy variant with creatine-kinase elevation and vanishing effect of immunoglobulins. Am J Case Rep. 2017;18:834–838.Hughes R. A. C., Donofrio P., Bril V. et al. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial // Lancet Neurol. – 2008. – Vol. 7, № 2. – Р. 136–144.Hughes R. A. C., Donofrio P., Bril V. et al. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–144.Magda P., Latov N., Brannagan T. H. et al. Comparison of Electrodiagnostic Abnormalities and Criteria in a Cohort of Patients with Chronic Inflammatory Demyelinating Polyneuropathy // Arch. Neurol. – 2003. – Vol. 60, № 12. – Р. 1755–1759.Magda P., Latov N., Brannagan T. H. et al. Comparison of Electrodiagnostic Abnormalities and Criteria in a Cohort of Patients with Chronic Inflammatory Demyelinating Polyneuropathy. Arch Neurol. 2003;60(12):1755–1759.Latov N., Deng C., Dalakas M. C. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy // Arch. Neurol. – 2010. – Vol. 67, № 7. – Р. 802–827.Latov N., Deng C., Dalakas M. C. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802–807.Kuwabara S., Misawa S., Mori M. et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: A five year follow up of 38 cases // J. Neurol. Neurosurg. Psychiatry. – 2006. – Vol. 77, № 1. – Р. 66–70.Kuwabara S., Misawa S., Mori M. et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: A five year follow up of 38 cases. J Neurol Neurosurg Psychiatry. 2006;77(1):66–70.Katzberg H. D., Rasutis V., Bril V. Home IVIG for CIDP: a focus on patient centred care // Can J. Neurol. Sci. – 2013. – Vol. 40, № 3. – Р. 384–388.Katzberg H. D., Rasutis V., Bril V. Home IVIG for CIDP: a focus on patient centred care. Can J Neurol Sci. 2013;40(3):384–388.Kuitwaard K., Hahn A. F., Vermeulen M. et al. Intravenous immunoglobulin response in treatmentnaïve chronic inflammatory demyelinating polyradiculoneuropathy // J. Neurol. Neurosurg. Psychiatry. – 2015. – Vol. 86, № 12. – P. 1331–1336.Kuitwaard K., Hahn A. F., Vermeulen M. et al. Intravenous immunoglobulin response in treatmentnaïve chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2015;86(12):1331–1336.Ritter C., Bobylev I., Lehmann H. C. Chronic inflammatory demyelinating polyneuropathy (CIDP): Change of serum IgG dimer levels during treatment with intravenous immunoglobulins // J. Neuroinflammation. – 2015. – Vol. 12, № 1. – Р. 1–8. http://dx.doi.org/10.1186/s12974-015-0361-1.Ritter C., Bobylev I., Lehmann H. C. Chronic inflammatory demyelinating polyneuropathy (CIDP): Change of serum IgG dimer levels during treatment with intravenous immunoglobulins. J Neuroinflammation [Internet]. 2015;12(1):1–8. Available at: http://dx.doi.org/10.1186/s12974-015-0361-1 (accessed 12.05.2019).Grimm A., Vittore D., Schubert V. et al. Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP // J. Neurol. – 2016. – Vol. 263, № 6. – Р. 1074–1082.Grimm A., Vittore D., Schubert V. et al. Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP. J Neurol. 2016;263(6):1074–1082.Vucic S., Black K., Baldassari L. E. et al. Long-term effects of intravenous immunoglobulin in CIDP // Clin. Neurophysiol. – 2007. – Vol. 118, № 9. – Р. 1980–1984.Vucic S., Black K., Baldassari L. E. et al. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neurophysiol. 2007;118(9):1980–1984.Nakanishi T., Suzuki N., Kuragano T. et al. Current topics in therapeutic plasmapheresis // Clin. Exp. Nephrol. – 2014. – Vol. 18, № 1. – Р. 41–49.Nakanishi T., Suzuki N., Kuragano T. et al. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol. 2014;18(1):41–49.Tombak A., Uçar M. A., Akdeniz A. et al. Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases // Indian J. Hematol. Blood Transfus. – 2017. – № 33 (1). – Р. 97–105.Tombak A., Uçar M.A., Akdeniz A. et al. Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases. Indian J Hematol Blood Transfus. 2017; 33(1):97–105.Szczepiorkowski Z. M., Winters J. L., Bandarenko N. et al. Guidelines On the Use Of Therapeutic Apheresis In Clinical Practice-Evidence Based Approach from the Apheresis Applications Committee of the American Society of Apheresis // Journ. of Cl. Apheresis. – 2010. – № 25. – Р. 83–177.Szczepiorkowski Z. M., Winters J. L., Bandarenko N. et al. Guidelines On the Use Of Therapeutic Apheresis In Clinical Practice-Evidence Based Approach from the Apheresis Applications Committee of the American Society of Apheresis. Journl of Clinical Apheresis. 2010; (25):83–177.Dyck P. J., Daube J., O’Brian P. et al. Plasma Exchange in Chronic Inflammatory Demyelinating Polyneuropathy // The New Engl. Journ. of Med. – 1986. – Vol. 314, № 8. – Р. 461–465.Dyck P. J., Daube J., O’Brian P. et al. Plasma Exchange in Chronic Inflammatory Demyelinating Polyneuropathy. The New England Journal of Medicine. 1986;314(8):461–465.Hahn A. F., Bolton C. F., Pillay N. et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study // Brain. – 1996. – Vol. 119, № 4. – Р. 1055–1066. URL: http://www.ncbi.nlm.nih.gov/pubmed/8813270 (дата обращения 12.05.2019).Hahn A. F., Bolton C. F., Pillay N. et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119(4):1055–1066. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8813270 (accessed 12.05.2019).SinanovićO., ZukićS., Burina A. et al. Plasmapheresis in neurological disorders: six years experience from University Clinical center Tuzla // F1000Research. – 2017. – № 6. – Р. 1234. URL: https://f1000research.com/articles/6-1234/v1 (дата обращения 12.05.2019).SinanovićO., ZukićS., Burina A. et al. Plasmapheresis in neurological disorders: six years experience from Uni versity Clinical center Tuzla. F1000Research [Internet]. 2017;6:1234. Available at: https://f1000research.com/articles/6-1234/v1 (accessed 12.05.2019).Vogl U., Leitner G., Dal-Bianco A. et al. Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation // Wien. Klin. Wochenschr. – 2016. – Vo l. 128, № 9–10. – Р. 384–386.Vogl U., Leitner G., Dal-Bianco A. et al. Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation. Wien Klin Wochenschr. 2016;128(9–10):384–386.Приказ Минздрава России от 24.12.2012 г. № 1537н «Об утверждении стандарта специализированной медицинской помощи при хронической воспалительной демиелинизирующей полиневропатии».Order of Ministry of Health of Russian Federation from 24.12.2012 no 1537n «About standart of specialized medical help to patients with chronic inflammatory demyelinating polyneuropathy confirmation».(In Russ.).Nobile-Orazio E., Cocito D., Jann S. et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP // J. Neurol. Neurosurg. Psychiatry. – 2015. – Vol. 86, № 7. – Р. 729–734.Nobile-Orazio E., Cocito D., Jann S. et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86(7):729–734.Viala K., Maisonobe T., Stojkovic T. et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy // J. Peripher. Nerv. Syst. – 2010. – Vol. 15, № 1. – Р. 50–56.Viala K., Maisonobe T., Stojkovic T. et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):50–56.Doneddu P. E., Cocito D., Manganelli F. et al. Atypical CIDP: Diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database // J. Neurol. Neurosurg. Psychiatry. – 2018. – № 1. – Р. 1–8.Doneddu P. E., Cocito D., Manganelli F. et al. Atypical CIDP: Diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2018;1:1–8.Rabin M., Mutlu G., Stojkovic T. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: Search for factors associated with treatment dependence or successful withdrawal // J. Neurol. Neurosurg. Psychiatry. – 2014. – Vol. 85, № 8. – Р. 899–904.Rabin M., Mutlu G., Stojkovic T. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: Search for factors associated with treatment dependence or successful withdrawal. J Neurol Neurosurg Psychiatry. 2014;85(8):899–904.Dyck P. J., Litchy W. J., Kratz K. M. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy // Ann. Neurol. – 1994. – Vo l. 36, № 6. – Р. 838–845. URL: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=24370922 (дата обращения 12.05.2019).Dyck P. J., Litchy W. J., Kratz K. M. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol [Internet]. 1994;36(6):838–845. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=24370922 (accessed 12.05.2019).Kaplan A., Brannagan T. H. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy // Muscle and Nerve. – 2017. – Vol. 55, № 4. – Р. 476–482.Kaplan A., Brannagan T.H. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve. 2017;55(4):476–482.Mahdi-Rogers M., Mccrone P., Hughes R. A. C. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England // Eur. J. Neurol. – 2014. – Vol. 21, № 1. – Р. 34–39.Mahdi-Rogers M., Mccrone P., Hughes R.A.C. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21(1):34–9.Blackhouse G., Xie F., Gaebel K. et al. Cost-Utility of Intravenous Immunoglobulin (Ivig) Compared With Corticosteroids for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada // Value Heal. – 2009. – Vol. 12, № 7. – Р. A380–A381. URL: http://linkinghub.elsevier.com/retrieve/pii/S1098301510748737 (дата обращения 12.05.2019).Blackhouse G., Xie F., Gaebel K. et al. Cost-Utility of Intravenous Immunoglobulin (Ivig) Compared With Corticosteroids for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Value Heal [Internet]. 2009;12(7):A380–A381. Available at: http://linkinghub.elsevier.com/retrieve/pii/S1098301510748737 (accessed 12.05.2019)..Cocito D., Grimaldi S., Paolasso I. et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis // Eur. J. Neurol. – 2011. – № 18 (12). – Р. 1417–1421.Cocito D., Grimaldi S., Paolasso I. et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;18(12):1417–1421.Mahdi-Rogers M., Brassington R., Gunn A. A. et al. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (Review) // Cochrane Database of Systematic Reviews. – 2017. – № 5 (CD003280). http://dx.doi.org/10.1002/14651858.CD003280.pub5.Mahdi-Rogers M., Brassington R., Gunn A. A. et al. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (Review). Cochrane Database of Systematic Reviews. 2017;(5) (CD003280). http://dx.doi.org/10.1002/14651858.CD003280.pub5.Velardo D., Riva N., Del Carro U. et al. Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases // J. Neurol. – 2017. – Vol. 264, № 5. – Р. 1011–1014.Velardo D., Riva N., Del Carro U. et al. Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. J Neurol. 2017;264(5):1011–1044.FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves / Z. Zhang, Z. Y. Zhang, U. Fauser, H. J. Schluesener // Exp. Neurol. – 2008. – Vol. 210, № 2. – Р. 681–690.Zhang Z., Zhang Z. Y., Fauser U., Schluesener H. J. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol. 2008;210(2):681–690.Hughes R., Dalakas M. C., Merkies I. et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial // Lancet Neurol. – 2018. – Vol. 17, № 8. – Р. 689–698.Hughes R., Dalakas M. C., Merkies I. et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018;17(8):689–698.

The authors declare that there are no conflicts of interest present.